The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $60.8bn by 2030.
How this report will benefit you
- Read on to discover how you can exploit the future business opportunities emerging in this sector.
- In this brand new 177-page report you will receive 100 charts– all unavailable elsewhere.
- The 177-page report provides clear detailed insight into the Top 26 asthma & COPD companies. Discover the key drivers and challenges affecting the market.
- By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
Profiles of the leading 26 asthma & COPD companies:
- Adamis Pharmaceuticals Corporation
- Aerocrine (Circassia)
- ALK-Abello A/S
- Amphastar Pharmaceuticals, Inc.
- AstraZeneca
- Boehringer Ingelheim
- Chiesi Farmaceutici
- Cipla
- Dimerix
- GlaxoSmithKline
- Innoviva
- Lallemand Pharma International
- Merck
- Mereo BioPharma Group plc
- MundiPharma
- Novartis
- Pulmatrix
- Respiratorius AB
- Roche
- Other companies
- An overview and analysis of the company
- A portfolio of the company’s marketed product and product pipeline
- Financial Information
- Revenue forecast from 2020-2030
- Recent developments
- Future Outlook
Key questions answered by this report:
- How is the Asthma & COPD Companies market evolving?
- What is driving and restraining the Asthma & COPD Companies market?
- What are the market shares of each segment of the overall Asthma & COPD Companies market in 2019?
- What will be the main driver for the overall market from 2019 to 2030?
- Will leading Asthma & COPD Companies broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- Who are the leading players and what are their prospects over the forecast period?
- What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
- How will the industry evolve during the period between 2019 and 2030?
US $
Euro €
GBP £